Partner with us to expand access to cervical cancer screening
We collaborate with governments, NGOs, laboratories, and global health partners to support scalable, evidence-based screening programs -particularly in settings where current models fail to reach enough women.
Why partner with Aprovix
Effective cervical cancer prevention depends not only on technology, but on how screening programs are designed, delivered, and sustained at scale.
Aprovix offers an evidence-based, clinically validated HPV self-sampling solution designed to integrate into real-world screening models and public health systems. We work with partners to support implementation approaches that are practical, scalable, and aligned with global best practices.
Increase participation in screening programs
Increase specificity of screening women 30-64 years old
Improve detection of CIN2-3 lesions compared to cytology
Studies show that Qvintip® can:
Who we partner with
-
We support national and regional screening programs seeking to expand coverage and participation through self-sampling approaches aligned with public health guidelines.
Partnerships may include:
Program design and piloting
Integration into national screening pathways
Support for scale-up and long-term implementation
-
We collaborate with NGOs and implementing partners to reach underserved populations through decentralized and community-based screening initiatives.
These partnerships may focus on:
Increasing participation among non-attenders
Supporting equity-focused screening approaches
Adapting programs to local cultural and logistical contexts
-
Qvintip is compatible with standard laboratory HPV platforms and leading PCR-based assays. We work with laboratories to support efficient sample handling, analysis, and reporting within screening programs.
-
We engage with global health stakeholders, technical partners, and funders to support evaluation, learning, and alignment with international best practices.